Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)

The objective of the study was to evaluate the effectiveness of empirical therapy with anidulafungin in patients with invasive candidiasis in real clinical practice in Russian healthcare institutions.Materials and methods. In a prospective multicenter (n = 23) ERA study in 2015–2017, 92 adult patien...

Full description

Bibliographic Details
Main Author: N. N. Klimko
Format: Article
Language:Russian
Published: ABV-press 2019-10-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/374
_version_ 1797855530241228800
author N. N. Klimko
author_facet N. N. Klimko
author_sort N. N. Klimko
collection DOAJ
description The objective of the study was to evaluate the effectiveness of empirical therapy with anidulafungin in patients with invasive candidiasis in real clinical practice in Russian healthcare institutions.Materials and methods. In a prospective multicenter (n = 23) ERA study in 2015–2017, 92 adult patients with invasive candidiasis were included. Depending on the type of anidulafungin administration, patients were divided into 2 comparable demographic groups. In the 1st group (n = 52; median age 50.5 ± 13.9 years (19–75 years); men ‒ 62 %), invasive candidiasis was microbiologically confirmed after the initiation of empirical anidulafungin therapy. In the 2nd group (n = 40; median age 47.15 ± 18.01 years (18–98 years); men — 65 %), patients received anidulafungin only after microbiological confirmation of invasive candidiasis. The groups did not statistically differ in risk factors, etiology of invasive candidiasis, the frequency of various organs damage, and also in APACHE II and SOFA score at the time of anidulafungin administration.Results and conclusion. Overall survival on the 30th day after laboratory confirmation of invasive candidiasis was statistically significantly higher in the empirical therapy group (66 % vs 58 %; p = 0.04 416). In addition, the empirical anidulafungin therapy was lead to a significant decrease in the duration of stay in intensive care units (13.5 ± 19.7 days vs 21 ± 15 days) and the total treatment time (22 ± 18 days vs 29 ± 21 days).
first_indexed 2024-04-09T20:25:09Z
format Article
id doaj.art-3989a80766e14e49babe8570ffe64e2d
institution Directory Open Access Journal
issn 1818-8346
2413-4023
language Russian
last_indexed 2024-04-09T20:25:09Z
publishDate 2019-10-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj.art-3989a80766e14e49babe8570ffe64e2d2023-03-30T20:15:12ZrusABV-pressОнкогематология1818-83462413-40232019-10-01143909710.17650/1818-8346-2019-14-3-90-97323Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)N. N. Klimko0I. I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaThe objective of the study was to evaluate the effectiveness of empirical therapy with anidulafungin in patients with invasive candidiasis in real clinical practice in Russian healthcare institutions.Materials and methods. In a prospective multicenter (n = 23) ERA study in 2015–2017, 92 adult patients with invasive candidiasis were included. Depending on the type of anidulafungin administration, patients were divided into 2 comparable demographic groups. In the 1st group (n = 52; median age 50.5 ± 13.9 years (19–75 years); men ‒ 62 %), invasive candidiasis was microbiologically confirmed after the initiation of empirical anidulafungin therapy. In the 2nd group (n = 40; median age 47.15 ± 18.01 years (18–98 years); men — 65 %), patients received anidulafungin only after microbiological confirmation of invasive candidiasis. The groups did not statistically differ in risk factors, etiology of invasive candidiasis, the frequency of various organs damage, and also in APACHE II and SOFA score at the time of anidulafungin administration.Results and conclusion. Overall survival on the 30th day after laboratory confirmation of invasive candidiasis was statistically significantly higher in the empirical therapy group (66 % vs 58 %; p = 0.04 416). In addition, the empirical anidulafungin therapy was lead to a significant decrease in the duration of stay in intensive care units (13.5 ± 19.7 days vs 21 ± 15 days) and the total treatment time (22 ± 18 days vs 29 ± 21 days).https://oncohematology.abvpress.ru/ongm/article/view/374anidulafungininvasive candidiasiscandida
spellingShingle N. N. Klimko
Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)
Онкогематология
anidulafungin
invasive candidiasis
candida
title Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)
title_full Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)
title_fullStr Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)
title_full_unstemmed Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)
title_short Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)
title_sort empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis era study results eraxisr in the russian federation
topic anidulafungin
invasive candidiasis
candida
url https://oncohematology.abvpress.ru/ongm/article/view/374
work_keys_str_mv AT nnklimko empiricalanidulafungintherapyincreasesthetreatmentefficacyininvasivecandidiasiserastudyresultseraxisrintherussianfederation